NeoStem Presents Five-Year Survival Data for Autologous Melanoma Immunotherapy Targeting Cancer Stem Cells at American Society of Clinical Oncology Annual Meeting

5-Year Overall Survival of Melapuldencel-T Cohort Was 33 Percent vs. 20 Percent for Patients Treated With Irradiated Autologous Tumor Cells for This Subset of Patients Phase 3 Study Planned for 2014, With Special Protocol Assessment May 29, 2014 NeoStem, Inc., a leader in the emerging cellular therapy industry, today announced results of a pooled analysis indicating that Melapuldencel-T, an investigational …